Next-Generation ADPR-Based Therapies for Enhanced Efficacy and Targeted Delivery
Legal Citation
Summary of the Inventive Concept
This inventive concept envisions a paradigm shift in the use of 5′-adenosine diphosphate ribose (ADPR) for treating adenovirus-related diseases or conditions, eye disorders, cancer, and other diseases or conditions. By leveraging nanoparticle-based delivery, combination therapies, sustained-release formulations, wearable patches, and gene editing tools, these next-generation ADPR-based therapies offer enhanced efficacy, targeted delivery, and improved patient outcomes.
Background and Problem Solved
The original patent disclosed methods for the use of ADPR for treating various diseases and conditions. However, these methods were limited by their lack of targeted delivery, potential side effects, and limited efficacy. The new inventive concept addresses these limitations by introducing novel delivery systems, combination therapies, and formulations that enhance the therapeutic potential of ADPR.
Detailed Description of the Inventive Concept
The new inventive concept comprises five key aspects: (1) nanoparticle-based delivery vehicles for targeted delivery of ADPR to affected cells; (2) combination therapies of ADPR with checkpoint inhibitors for enhanced immune response; (3) sustained-release formulations of ADPR for extended therapeutic concentrations; (4) wearable patches for transdermal administration of ADPR with real-time dose adjustment; and (5) gene editing tools to enhance the efficacy of ADPR. These innovations enable more effective treatment of adenovirus-related diseases or conditions, eye disorders, cancer, and other diseases or conditions.
Novelty and Inventive Step
The new claims introduce a novel and non-obvious combination of ADPR with advanced delivery systems, combination therapies, and formulations that significantly enhance its therapeutic potential. The use of nanoparticle-based delivery, wearable patches, and gene editing tools represents a paradigm shift in the field, making the original inventive concept obsolete.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different nanoparticle materials, varying the ratio of ADPR to checkpoint inhibitors, or incorporating additional therapeutic agents into the sustained-release formulations. Variations could also include the development of implantable devices or injectable formulations for ADPR delivery.
Potential Commercial Applications and Market
The next-generation ADPR-based therapies have significant commercial potential in the treatment of adenovirus-related diseases or conditions, eye disorders, cancer, and other diseases or conditions. Target industries include pharmaceutical companies, biotechnology firms, and medical device manufacturers. The market potential is substantial, with an estimated value of billions of dollars in the next decade.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically focused on therapeutic compositions for treating viral infections, inflammatory conditions, and targeted drug delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in pharmaceutical sciences, biotechnology, or biomedical engineering, possessing expertise in drug formulation, targeted delivery mechanisms, and therapeutic composition design
Obviousness Rationale
A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's core ADPR therapeutic approach. The disclosed nanoparticle delivery, combination therapies, and sustained-release formulations are logical technological progressions that apply standard pharmaceutical engineering techniques to enhance the original ADPR therapeutic method. These variations demonstrate incremental improvements using well-established drug development strategies that would be apparent to a skilled practitioner in the field.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,561 |
|---|---|
| Title | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) |
| Assignee(s) | Invirsa, Inc. |